In an exciting breakthrough for those suffering from chronic rhinitis, Neurent Medical has unveiled promising six-month results from their groundbreaking PARAGON clinical study, published in the Ear, Nose & Throat Journal. This study assesses the NEUROMARK System, a non-surgical radiofrequency ablation device targeting chronic rhinitis, and the results are astonishing!

The PARAGON study, which included 80 participants, proved that treatment with the NEUROMARK System led to significant improvements not just in nasal symptoms, but also in associated ear issues and overall quality of life. "This research provides compelling evidence that the NEUROMARK System significantly alleviates the burdens of chronic rhinitis," stated the researchers involved.

Key Findings of the PARAGON Study:

The primary efficacy endpoint — changes in the reflective Total Nasal Symptom Score (rTNSS) — was met with an exceptional statistical significance (p < .0001), showing that patients experienced marked relief from symptoms over the six-month period.

An impressive 91% of participants achieved a minimal clinically important difference (MCID) with at least a one-point improvement in their rTNSS scores within the same timeframe.

Additional assessments, including the Eustachian Tube Dysfunction Questionnaire (ETDQ-7), showed substantial improvements in ear-related symptoms, which often accompany chronic rhinitis, again with high statistical significance (p < .0001).

All measures of nasal obstruction (NOSE) and quality of life (mini-RQLQ) were significantly bettered at every evaluation point (p < .0001), showcasing the comprehensive effectiveness of the treatment.

Participants with both allergic and non-allergic rhinitis experienced similar levels of improvement, demonstrating the broad applicability of the NEUROMARK System.

Dr. Greg Davis, the lead investigator of the study, expressed his enthusiasm: "This study unequivocally shows the potential of the NEUROMARK System in addressing not just nasal congestion, but ear problems related to Eustachian tube dysfunction. This represents a pioneering approach to managing these debilitating symptoms."

Brian Shields, CEO of Neurent Medical, added, "We are thrilled with the results from the PARAGON study, as they reveal the effectiveness of our NEUROMARK System in providing substantial relief to chronic rhinitis sufferers, regardless of their underlying condition. This reinforces our mission to innovate non-invasive solutions that significantly enhance patients' quality of life in an area where more effective treatments are urgently needed."

As healthcare continues to evolve, the NEUROMARK System stands out as a potentially game-changing option for individuals grappling with chronic sinonasal diseases, marking a pivotal shift toward more efficient and less invasive treatments. With these compelling results at hand, the future looks bright for chronic rhinitis management!